Viridian Metals Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 94
- Market Cap
- $956.7M
- Introduction
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease
Viridian Therapeutics announced positive Phase 1/2 trial results for VRDN-001 in treating thyroid eye disease (TED), showing significant improvement in symptoms with a favorable safety profile. The global Phase 3 THRIVE program has been initiated, with promising data supporting VRDN-001 as a potential new treatment option for TED patients.
© Copyright 2025. All Rights Reserved by MedPath